Surbek D, Bösiger H, Pavic N, Huber P, Almendral A C, Holzgreve W
Universitäts-Frauenklinik Basel.
Z Geburtshilfe Neonatol. 1997 Jan-Feb;201(1):15-20.
The accuracy of cervicovaginal fetal fibronectin as a predictor of preterm birth was studied in patients with increased risk for preterm delivery (according to the Creasy-score). In a prospective blind observational study the smear from the posterior fornix vaginae of 56 pregnant patients without PROM was examined using a quantitative immunoassay for the detection of fetal fibronectin. The patients who tested positively for fetal fibronectin had significantly more preterm deliveries than those with a negative result (CHI square-test, p < 0.01, RR 5.1). Overall, sensitivity, specificity, positive and negative predictive values were 56%, 87%, 45% and 91%, respectively. In patients with preterm labor these values were 75%, 87%, 60%, and 93%, respectively. No patient with a negative result delivered preterm during the following two weeks. It is concluded that performing the fetal fibronectin test in patients with preterm labor is useful for the prediction of preterm birth. Routine testing in patients at increased risk (asymptomatic patients) is not recommended for lack of effectiveness.
在早产风险增加的患者（根据Creasy评分）中，研究了宫颈阴道胎儿纤连蛋白作为早产预测指标的准确性。在一项前瞻性盲法观察研究中，使用定量免疫测定法对56例无胎膜早破的孕妇阴道后穹窿涂片进行检查，以检测胎儿纤连蛋白。胎儿纤连蛋白检测呈阳性的患者早产的比例明显高于检测结果为阴性的患者（卡方检验，p<0.01，相对危险度5.1）。总体而言，敏感性、特异性、阳性预测值和阴性预测值分别为56%、87%、45%和91%。在早产患者中，这些值分别为75%、87%、60%和93%。检测结果为阴性的患者在接下来的两周内均未早产。结论是，对早产患者进行胎儿纤连蛋白检测有助于预测早产。由于缺乏有效性，不建议对风险增加的患者（无症状患者）进行常规检测。
